Title : High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).

Pub. Date : 1995

PMID : 7579504






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In pre-clinical and limited clinical studies, high doses ( > or = 200 mg/day) of the triphenylethylene derivative toremifene showed activity in estrogen receptor (ER) negative and ER-unknown metastatic breast cancer after progression on tamoxifen, and a mechanism of action independent of hormone receptor binding was speculated. Toremifene nuclear receptor subfamily 4 group A member 1 Homo sapiens
2 The CALGB conducted a Phase II trial (CALGB 8945) to test the efficacy of high dose toremifene in a population of patients who had hormone receptor-negative, metastatic breast cancer with limited prior chemotherapy exposure, good performance status, and measurable disease. Toremifene nuclear receptor subfamily 4 group A member 1 Homo sapiens